Kidney transplant remains the best type of renal replacement therapy in most patients with end-stage kidney disease, even in those with high immunologic risk. Immunosuppression in these patients is regarded as more complex, owing to the higher risk of both acute and chronic rejection. The advent of induction immunosuppression has resulted in a lower incidence of acute rejection and consequently improved shortterm patient and allograft outcomes. Indeed, the use of these agents, especially in high-risk recipients, has become standard of care at most transplant centers. Transplant physicians are constantly faced with the challenge of estimating the recipients' immunologic risk and tailoring their immunosuppression ac cordingly. This review article aims to provide an up-to-date evaluation of the various studies available, which investigated the use of induction agents in kidney transplant, specifically in high-risk recipients. It evaluates the use of the most frequently used polyclonal antibody (rabbit antithymocyte globulin) versus the less commonly used monoclonal antibody alemtuzumab, superseded agents such as muromonab-CD3, and potentially emerging agents such as rituximab, bortezomib, and eculizumab. With this systematic review, we hope to inform the scientific community and facilitate this controversial decision through the implementation of robust scientific evidence.
Introduction
The human immune system has evolved over millions of years to ensure adequate protection against various microbial pathogens present in our environment. The antigen-host interaction is initiated via a process called allorecognition, whereby any foreign protein is exhibited on an HLA antigen molecule and becomes recognized by the host immune system. 1 It is thought that this process starts immediately once the arterial clamps are snapped open and the transplanted organ is perfused for the first time by the host circulation. T lymphocytes orchestrate the subsequent effector response, leading to rejection of the transplanted tissue. With the exception of transplant between monozygotic twins, immunosuppression remains an integral part of modern transplant medicine. In HLA-and ABOcompatible kidney transplant, immunosuppression falls under 3 main categories: induction, maintenance, and rescue therapy. Induction immunosuppression is a prophylactic treatment using biologic agents that deplete or modulate the activation of lymphocytes in the peritransplant and immediate posttransplant periods. The principal aim is to alter this highly immunogenic instance and perhaps facilitate late introduction of calcineurin inhibitors, especially when delayed graft function (DGF) is expected. In addition, oral agents might not be sufficiently effective in the first few days because of their inherent pharmacokinetics properties. Various randomized controlled studies and meta-analyses have consistently showed that induction therapy and maintenance immunosuppression are associated with less rejection episodes compared to maintenance therapy alone. [2] [3] [4] The most favorable induction strategy depends on the estimated immunologic risk and remains a rather debatable topic among different transplant centers. 5 According to the Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients annual data, there was an overall reduction in the use of interleukin 2 receptor antagonists (IL-2ra) and a corresponding rise in use of antilymphocyte agents (ALAs), reaching 56 .2% of all recipients in 2012. 6 
Aims and Methods
Our aim of this critical reflection was to systematically investigate this controversial subject in high-risk kidney transplant recipients. This critical review was limited to studies that investigated the effects of induction agent on the short-and long-term outcomes of transplant recipients classified as high immunologic risk. Literature searches were performed via MEDLINE, EMBASE, PubMed, Google Scholar, and Scopus, using the following medical subject headings: induction, prophylactic, therapy/immunosuppression, antilymphocyte, biologic or biologics, alemtuzumab, IL-2ra (basiliximab/daclizumab), rituximab, bortezomib, eculizumab, high immunologic risk, and kidney or renal transplant. All relevant registry analyses, randomized controlled trials, and retrospective cohort studies describing the use of induction agents in high-risk adult kidney transplant patients were included. Case reports or series that included ≤ 3 patients were excluded.
Induction immunosuppressive agents
Induction immunosuppression falls under 2 main categories: (1) IL-2ra, also known as nondepleting agents, which include basiliximab and daclizumab; and (2) ALAs, also known as depleting agents, which are further subdivided into the following: monoclonal agents such as muromonab-CD3, alemtuzumab, and rituximab; and polyclonal agents, including rabbit antithymocyte globulin (rATG) and equine antithymocyte globulin (ATGAM; Pfizer).
Muromonab-CD3
Muromonab-CD3 (Orthoclone [OKT3] ; Centocor Ortho Biotech, L.P) is a murine monoclonal antibody directed against the CD3 receptor on T lymphocytes ( Figure  1 ). Antibody-receptor interactions induce widespread T-lymphocyte dysfunction. 7, 8 Muromonab-CD3 has been associated with severe cytokine release syndrome, pulmonary edema, and gastrointestinal and neurologic disturbances. 9 There is paucity of quality data on its clinical use, safety profile, and effectiveness. Its use in kidney transplant has been largely superseded by safer induction agents, and it was recently withdrawn from the US market.
Antithymocyte globulin
Antithymocyte globulin (ATG) is produced by active immunization of rabbits (rATG) or horses (ATGAM) with human lymphoid tissue. The mechanism of action is not completely understood, but it ultimately leads to complement lysis of various immunocompetent cell lineages. Recovery of the immune system may take months to years and may not recover entirely, especially with increasing age. 10 The main adverse effects include cytokine release syndrome, pyrexia, hypotension, thrombocytopenia, leukopenia, and serum sickness. 9
Meta-analyses investigating the use of depleting antilymphocyte agents versus no induction
In 1997, a meta-analysis conducted by Szczech and associates 3 analyzed 7 randomized controlled trials involving 794 patients receiving either muromonab-CD3 or polyclonal ALA versus no treatment or placebo. [11] [12] [13] [14] [15] [16] [17] This demonstrated an overall reduction in deceased-donor graft failure with ALA and a 6% increase in survival in the first 2 years. 3 19 Basiliximab was given at standard dose and rATG was given at 1.5 mg/kg for 5 to 7 days. All patients were maintained on tacrolimus or cyclosporine, MMF, and steroids. As with many retrospective studies, the baseline characteristics indicated considerable center bias. Indeed, patients with higher PRA, who had been retransplanted, and who had received deceased-donor kidneys were significantly more likely to receive rATG induction. Although these patients had a higher immunologic risk, there was no significant difference in the rate of acute rejection and graft or patient survival at 1 year. However, there was a significant increase in cytomegalovirus infections and DGF rates. 22 Patients who received no induction were used as the reference group, and all patients were maintained on tacrolimus and MMF with or without steroids. The composite triple endpoint was defined as allograft rejection, graft failure, or patient death at 6 months after transplant. Patients who received rATG together with steroids were more likely to be of black ethnicity, obese, presensitized, recipients of an HLA-DR mismatched graft from older donors, and with higher incidences of cardiovascular comorbidities and DGF. Although patients who received rATG had a higher immunologic risk, the risk of the triple endpoint was significantly lower in the rATG group than in the basiliximab group regardless of steroid use (adjusted odds ratio of 0.78; 95% confidence interval, 0.69-0.87 with steroids and adjusted odds ratio of 0.66; 95% confidence interval, 0.44-1.00 without steroids). A 2.7% and 4.7% absolute reduction in the incidence of triple endpoint was shown in the rATG versus basiliximab group in those patients who received steroids and those who did not. Although registry analyses provide "real life"
Retrospective analyses using registry data
long-term patient data and are useful benchmarks for future studies, they should always be interpreted with caution; recognizing their limitations is paramount before drawing conclusions. Nonetheless, these published analyses suggested that rATG is associated with less acute rejection and better outcomes than IL-2ra in high-risk transplant patients.
Randomized controlled trials investigating the use of antithymocyte globulin induction in high-risk kidney transplant patients
Thibaudin and associates conducted the first randomized, prospective, single-center study comparing rATG (n = 42) with no ATG (n = 42) in addition to standard therapy consisting of cyclosporine, azathioprine, and steroids in presensitized kidney transplant recipients between 1991 and 1995. 23 The study included patients who received first or second transplants, patients who received deceased-or living-donor transplants, and patients with current or historical positive B-cell crossmatch. Panel reactive antibody was calculated using the lymphocytotoxic method, and pre-sensitized was defined as patients with PRA > 5%. Rabbit antithymocyte globulin lowered the incidence of BPAR from 64% to 38% (P = .02) and was beneficial in all presensitized patients. There was a borderline significant improvement in graft survival at 1 year. The second randomized controlled trial was conducted by Brennan and associates. 24 This was a prospective, international multicenter, open-label, industrysponsored randomized controlled trial that compared short courses of ATG (n = 141) with standard basiliximab dose (n = 137) in patients at high risk of acute rejection or DGF. At 12 months, the incidence of BPAR was significantly lower in the ATG group than in the basiliximab group (15.6% vs 25.5%; P = .02) as was the severity of acute rejection requiring the use of rescue ALA (1.4% vs 8%; P = .005). In contrast, the incidences of graft loss, DGF, patient death, major adverse effects, and malignancy were similar. Patients treated with ATG had a higher incidence of overall infection episodes (85.8% vs 75.2%; P = .03). Interestingly, cytomegalovirus infections were significantly higher in the IL-2ra group (7.8% vs 17.5%; P = .02). Brennan and associates continued follow-up of the US patients for 5 years. 25 Composite endpoints were BPAR, DGF, graft loss, and patient death. The lower incidence of BPAR (15% vs 27%; P = .03) and lower incidence of composite endpoint (37% vs 51%; P = .04) in the ATG group was sustained even at 5 years. In 2009, Noel and associates conducted another prospective, multicenter, investigator-sponsored randomized controlled trial, but this one was in Europe. 26 This study provided a head-to-head comparison of the efficacy and safety of rATG (n = 113) versus daclizumab (n = 114) among high-risk kidney transplant patients. High immunologic risk was defined as current PRA of > 30%, peak PRA > 50%, loss of a first kidney allograft attributed to rejection within 2 years, and 2 or 3 previous allografts. Patients treated with rATG had a lower incidence of both BPAR (15.0% vs 27.2%; P = .016) and steroid-resistant rejection (2.7% vs 14.9%; P = .002) at 1 year. The overall graft and patient survival rates were similar in the 2 arms, although patients who were free of rejection episode had higher graft survival compared with those with rejection (87.2% vs 75.0%; P = .037). There was less incidence of DGF in the rATG group than in the daclizumab group (31.5% vs 44.6%; P = .044). These advantages were unfortunately hindered by a significantly higher mean number of bacterial infections per patient (2.5 ± 1.8 vs 1.8 ± 1.2; P = .014) and a trend toward higher incidence of cytomegalovirus viremia requiring treatment (18.6% vs 10.5%; P = .093) in the rATG group compared with the daclizumab group. Hellemans and associates followed the same cohort of patients for 5 years. 27 Again, treatment with rATG was associated with lower incidence of BPAR compared with daclizumab (14.2% vs 26.0%; P = .035). Overall graft and patient survival rates remained similar in the 2 groups even at 5 years, although overall graft survival was significantly higher in patients without BPAR (81.0% vs 54.8%; P < .001). Table 1 summarizes the above-mentioned randomized controlled trials.
In conclusion, Noel and associates 26 enrolled a higher number of retransplant patients (70% vs 10%) and patients with higher PRA levels (peak 72% vs 14%) compared with that shown in the study by Brennan and associates. 24 Target ATG dose was also slightly higher (8.75 mg vs 7.5 mg/kg), used daclizumab rather than basiliximab, and maintained patients on tacrolimus (more common in modern regimens) rather than cyclosporine. However, the overall outcome was outstandingly similar, with a lower BPAR at 1 year and with no significant differences in the overall allograft or patient survival between the 2 arms.
Comparison between the 2 major antithymocyte globulins
Brennan and associates conducted a randomized, double blind, single-center comparison of thymoglobulin (n = 48) at 1.5 mg/kg versus equine ATG (n = 24) at 15 mg/kg. 28 All patients received immunosuppression with cyclosporine, MMF or azathioprine, and steroids. The thymoglobulin group, when compared with the group that received equine ATG, had less incidence of acute rejections (4% vs 25%; P = .014), were more likely to be event free (patient survival, graft loss, or rejection; 94% vs 63%; P = .001), and had less adverse effects (P = .013) at 1 year. At 5 years, Hardinger and associates established more significant results. 29 Patient who received thymoglobulin were more likely to remain event free (73% vs 33%; P ≤ .001) and without acute rejection (92% vs 66%; P = .007) compared with equine ATG. The difference in the event-free survival was sustained even at 10 years. 30 The difference in graft survival was however no longer statistically significant at 10 years. Kim and associates conducted a retrospective, single-center study in Korea, comparing patients who received thymoglobulin (n = 152) versus equine ATG (n = 84) between 1997 and 2010. 31 All patients received tacrolimus or cyclosporine, MMF, and steroids. Patients receiving thymoglobulin were significantly older, had higher body mass index, had longer duration on dialysis, and had a higher number of retransplants. Thymoglobulin was significantly associated with higher incidence of DGF when compared with equine ATG (7.9% vs 0%; P = .005). Death-censored graft survival at 5 years was significantly higher in the thymoglobulin group than in the equine ATG group (96.8% vs 88.7%; P = .027), but creatinine levels and number of acute rejection episodes were similar. As with all retrospective studies, a degree of variability in the baseline characteristics is inevitable, and one should interpret these findings with a certain degree of caution.
Studies investigating the optimal antithymocyte globulin dose
Bacterial and viral opportunistic infections were lower when the total dose of ATG did not exceed 7 mg/kg. 32 Gurk-Turner and associates conducted a retrospective cohort study looking specifically at the optimal ATG dose in high-risk kidney transplant recipients in the United States between 2000 and 2005. 33 Patients were considered high risk if they had required retransplants or had a PRA > 40%. All patients received tacrolimus, MMF, and steroids. The absolute CD3 lymphocyte, platelet, and total white blood cell counts were closely monitored. At 18 months, there was no significant difference in the overall graft survival, and at 12 months there was no significant difference in the incidence of BPAR or serum creatinine levels between patients who received higher dose rATG (≥ 7.5 mg/kg; n = 63) and those who received a lower dose (≤ 7.5 mg/kg; n = 33).
Alemtuzumab
Alemtuzumab is a recombinant, humanized, monoclonal antibody, which targets the CD52 cell surface antigen present on T and B lymphocytes, natural 26 killer cells, some monocytes, and granulocytes ( Figure 1 ). These cells will subsequently undergo a sustained complement-mediated lysis. The main adverse effects include mild cytokine release syndrome, pancytopenia, autoimmune thrombocytopenia, and thyroid disease. 9
Retrospective studies investigating the use of alemtuzumab versus antithymocyte globulin Schadde and associates investigated induction with alemtuzumab (n = 61) versus IL-2ra (n = 43) in lowrisk recipients and alemtuzumab (n = 20) versus ATG (n = 21) in high-risk recipients of kidneys from donors after cardiac death. 34 High-risk was defined as PRA ≥ 20%, retransplant, and African American background. All patients received triple maintenance therapy with calcineurin inhibitors, MMF, and steroids. There was no significant difference in the rejection rate or glomerular filtration rate between the 2 induction modalities, but there was a trend of increased graft and patient death (P = .055) in patients who received alemtuzumab compared with ATG in the high-risk group. Noureldeen and associates conducted a single-center retrospective study to investigate alemtuzumab (single 30-mg dose; n = 68) versus rATG (total dose of 6 mg/kg; n = 40) between 2009 and 2011. 35 Maintenance immunosuppression consisted of tacrolimus, MMF, and steroids, which were discontinued in all except in sensitized recipients. Acute rejection episodes were similar in both groups. However, the alemtuzumab group had significantly higher incidence of antibody-mediated rejection than the rATG group (15% vs 2.5%; P = .008) at 1 year. This difference can probably be attributed to a significantly higher use of maintenance steroids in the rATG group, giving a favorable outcome.
Randomized controlled trials investigating the use of alemtuzumab versus antithymocyte globulin in high-risk renal transplants patients
This area of transplant immunology is characterized by small, underpowered studies with relatively short follow-up. Thomas and associates conducted a prospective, open-label randomized controlled trial that investigated the use of alemtuzumab induction with tacrolimus monotherapy versus rATG induction with standard triple therapy in high-risk kidney transplant recipients, defined as patients who currently have or have a history of PRA > 20% or retransplant. 36 In an interval report published in 2007, the incidence of BPAR, infections, and cumulative patient and graft survival were similar at 1 year. Lu and associates conducted a similar study in the Chinese population, including 23 high-risk patients defined as PRA > 20%. 37 These patients were randomized to either alemtuzumab or rATG, with both groups receiving standard maintenance immunosuppression composed of tacrolimus, MMF, and steroids. Similar creatinine levels, graft and patient survival rates, and freedom from rejection episodes were reported at the 2-year follow-up. Although both studies were underpowered to draw any firm conclusions, the results obtained are encouraging and suggest that alemtuzumab induction may be a safe option in high-risk patients. In another single-center randomized controlled trial conducted by Farney and associates, a significantly higher rate of freedom from rejection episodes was reported in the alemtuzumab arm compared with the rATG arm. 38 These results should be interpreted with the understanding that the study population was a combination of kidney alone, kidney and pancreas, and pancreas transplant recipients. Immunologic risk was different, with most patients belonging to the low immunologic risk group. Finally, maintenance immunosuppression also differed depending on the level of immunologic risk, with some patients having early steroid withdrawal and others having rapid withdrawal. These randomized controlled trials were followed by a study by Hanaway and associates. This was the largest, open-label, multicenter randomized controlled trial to date. 39 Patients received either alemtuzumab or conventional induction therapy, which involved basiliximab in low-risk (n = 335) and rATG (n = 139) in high-risk patients. High risk was defined as patients with current or history of PRA ≥ 20%, retransplant patients, or black patients. In the high-risk group, 70 patients received alemtuzumab and 69 received rATG. Maintenance immunosuppression included tacrolimus, MMF, and steroids (discontinued on day 5). Among the high-risk patients, there was no significant difference in BPAR rate at 6, 12, and 36 months between patients who received alemtuzumab and those who received rATG. The 3-year KaplanMeier actuarial patient survival curves in the highrisk group showed a trend toward better patient survival in the alemtuzumab group than in the rATG group (99% vs 91%; P = .07). There was no significant difference in death-censored graft survival in the high-risk group when alemtuzumab was compared with rATG at 3 years. Among high-risk patients, there was a significantly higher rate of infection episodes in the rATG group than in the alemtuzumab group (81% vs 60%; P = .009). Table 2 summarizes the above-mentioned RCTs.
Rituximab, Bortezomib, and eculizumab
Rituximab is a chimeric monoclonal antibody directed against the CD20 transmembrane protein found on B lymphocytes (Figure 1) . 40 After binding, the B lymphocytes undergo lysis via both complementdependant and complement-independent pathways. 41 van den Hoogen and associates conducted a randomized controlled trial to assess the efficacy of rituximab as an induction agent in both low-and highrisk kidney transplant recipients. 42 In this study, a PRA of > 6% or retransplant were considered as factors indicating high immunologic risk. Patients were randomized to either a single dose of 375 mg/m 2 of rituximab (n = 138) or placebo (n = 142). Maintenance immunosuppression consisted of tacrolimus, MMF, and steroids. At 6 months, the overall incidence of BPAR was similar in the 2 arms. However, high-risk patients not treated with rituximab had a significantly higher incidence of acute rejection (38.2%) than rituximab-treated high-risk patients (17.9%), rituximab-treated low-risk patients (16.4%), and low-risk patients treated with placebo (15.7%) (P = .004). Neutropenia was one of the main adverse events in patients receiving rituximab when compared with those who did not (24.3% vs 2.2%; P < .001). To our knowledge, this is the only study to date that has investigated rituximab as an induction agent rather than a desensitizing agent. Results suggest that rituximab may have a role in the induction strategy of kidney transplant. Longer multicenter randomized controlled trials are essential to substantiate these results and to evaluate effectiveness against the standard induction therapies that are currently used.
We found no studies that investigated bortezomib and eculizumab as induction agents in ABO-and HLA antigen-compatible kidney transplant patients. These relatively novel agents are still sparingly used in the field of kidney transplant, and most data are available via case reports. Their use is reserved for desensitization in HLA antigenincompatible trans plant and resistant antibodymediated rejection. [43] [44] [45] [46] Eculizumab is also effective for treatment of recurrent atypical hemolytic uremic syndrome. 47 
Discussion
The use of ATG as an induction agent in high-risk transplant recipients definitely confers significantly less BPAR than IL-2ra. This is however achieved with the caveat of higher infection episodes. The use of ATG in this subgroup of renal transplant patients failed to convey any significant advantages in terms of graft or patient survival. These conclusions are based on consistent moderate-quality evidence, including 3 robust randomized controlled trials, several registry analyses, and retrospective cohort studies. One has to appreciate that the evidence is less inclusive than with IL-2ra use in transplant. Logically, it makes sense to stratify patients according to their immunologic risk and to reserve rATG for high-risk transplant patients, so that its effectiveness against acute rejection is maximized and the exposure to potential serious adverse effects is minimized. Improvement in overall graft and patient survival rates is certainly considered one of the most important measurable targets in kidney transplant; however, one cannot simply use acute rejection as a surrogate marker for graft or patient survival. Conversely, numerous studies have established acute rejection as an independent risk factor for graft loss. [48] [49] [50] [51] [52] [53] [54] In addition, patients who develop early rejection were at a higher risk of developing chronic allograft rejection. 55, 56 In 1 study, the cause for graft failure was attributed to antibody-mediated rejection in one-half of patients requiring an indication biopsy. 57 High-risk transplant recipients induced with IL-2ra may ultimately require a higher cumulative dose of steroids or still require ATG at a later stage as rescue therapy. Prevention of acute rejection episodes by use of appropriate induction agents may ultimately result in a lower overall immunosuppression burden and perhaps decreased risk of infection and cardiovascular mortality. Indeed, Schweer and associates established a higher incidence of posttransplant type 2 diabetes mellitus in patients requiring rescue treatment with steroid pulses. 58 There have been few head-to-head comparisons on the use of alemtuzumab versus ATG in high-risk renal transplant patients. Data available suggest that alemtuzumab does not confer any significant additional advantages over ATG. To identify even small differences in graft and/or patient outcomes, randomized controlled trials need to be adequately powered and patients followed for longer periods. Long-term studies specifically investigating develop ment of de novo donor-specific antibodies with different induction regimens are particularly essential.
The economic aspect of such preparations is another important issue worth considering. Although this might not be of significant concern in developed countries where health services are free at the point of delivery, it certainly matters in countries where the burden of immunosuppressive funding is paid by the patients. Even though, the costs of these preparations vary considerably between countries, typically ATG is more expensive than Basiliximab, Rituximab or Alemtuzumab (Campath; Genzyme). Alemtuzumab is of recently being marketed under a different brand name for multiple sclerosis (Lemtrada; Genzyme), and the price has significantly increased. Additionally, side effects, treatment failure requiring alternative treatment and, of course, hospital admission complicates any cost analysis.
Considering this cost variation and until novel data become available, it is reasonable to use ATG for induction in high-risk renal transplant patients, provided that adequate antimicrobial prophylaxis is instituted. In an editorial published in 2009, Mandelbrot presented analogous suggestions: administration of IL-2ra in low-risk transplant patients and administration of rATG in high-risk transplant patients. 59 This recommendation is also in line with the Kidney Disease Improving Global Outcomes clinical practice guideline for the care of kidney transplant recipients issued in 2009. 5 Another important consideration is the actual definition of a "high-risk transplant" patient. Most studies described here have used different definitions; therefore, predicting pretransplant risk is another source of controversy. Table 3 provides a tentative definition of high-risk transplant by summarizing various studies included in this review. The objective of such an approach is to standardize therapy and to assist nephrologists tailoring induction therapy according to their patient's baseline characteristics. 
Conclusions
The use of ATG as induction agent in high-risk kidney transplant recipients is associated with less acute rejections than with IL-2ra, although possibly at the expense of a higher rate of infection. This conclusion is based on moderate-quality evidence delivered by robust randomized controlled trials that provided head-to-head comparisons with IL-2ra. Although these studies were not intended to investigate the optimal dose of ATG, the cumulative dose ranged from 7.5 to 10 mg administered perioperatively and during the immediate posttransplant period. The use of a single 30-mg dose of alemtuzumab appears to be equally effective to ATG at least in the short term. One promising advantage is the milder adverse effect profile; however, more robust data with longer follow-up are required. Unfortunately, both agents have failed to convey any significant advantages in terms of graft and patient survival rates. Considering the evidence to date, ATG should be the favored induction agent in high-risk renal transplant patients. Finally, multicenter collaboration and large registry data analyses are required to standardize the definition of "high immunologic risk," which to date remains one source of significant bias and controversy in this field of kidney transplant.
